Cadrenal Therapeutics, Inc. financial data

Symbol
CVKD on Nasdaq
Location
Ponte Vedra, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 372% % -36%
Debt-to-equity 37% % 77%
Return On Equity -280% % -96%
Return On Assets -204% % -73%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2,075,845 shares 25%
Common Stock, Shares, Outstanding 2,059,754 shares 67%
Entity Public Float $4,008,255 USD -37%
Common Stock, Value, Issued $2,059 USD 67%
Weighted Average Number of Shares Outstanding, Basic 2,044,033 shares 85%
Weighted Average Number of Shares Outstanding, Diluted 2,044,033 shares 85%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $4,971,476 USD 64%
General and Administrative Expense $9,696,297 USD 97%
Operating Income (Loss) $14,674,498 USD -85%
Nonoperating Income (Expense) $288,857 USD -15%
Net Income (Loss) Attributable to Parent $14,385,641 USD -89%
Earnings Per Share, Basic -8 USD/shares 41%
Earnings Per Share, Diluted -8 USD/shares 41%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $3,860,082 USD -12%
Assets, Current $4,079,726 USD -13%
Property, Plant and Equipment, Net $5,729 USD 604%
Operating Lease, Right-of-Use Asset $2,197 USD -92%
Other Assets, Noncurrent $2,167 USD -43%
Assets $4,087,622 USD -13%
Accounts Payable, Current $614,127 USD 24%
Employee-related Liabilities, Current $966,575 USD 62%
Accrued Liabilities, Current $738,548 USD -3.8%
Liabilities, Current $1,352,675 USD 6.8%
Liabilities $1,352,675 USD 6.8%
Retained Earnings (Accumulated Deficit) $35,921,155 USD -67%
Stockholders' Equity Attributable to Parent $2,734,947 USD -20%
Liabilities and Equity $4,087,622 USD -13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,648,755 USD -153%
Net Cash Provided by (Used in) Financing Activities $1,970,136 USD
Net Cash Provided by (Used in) Investing Activities $3,251 USD
Common Stock, Shares Authorized 75,000,000 shares 0%
Common Stock, Shares, Issued 2,059,754 shares 67%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3,860,082 USD -12%
Deferred Tax Assets, Valuation Allowance $4,744,000 USD 118%
Deferred Tax Assets, Gross $4,744,000 USD 117%
Operating Lease, Liability $2,232 USD -92%
Depreciation $6,725 USD 225%
Payments to Acquire Property, Plant, and Equipment $3,251 USD
Lessee, Operating Lease, Liability, to be Paid $2,219 USD -0.58%
Operating Lease, Liability, Current $2,232 USD -91%
Lessee, Operating Lease, Liability, to be Paid, Year One $22,742 USD 1.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $132 USD -95%
Deferred Tax Assets, Operating Loss Carryforwards $2,748,000 USD 150%
Preferred Stock, Shares Authorized 7,500,000 shares 0%
Additional Paid in Capital $38,654,043 USD 55%
Preferred Stock, Shares Outstanding 7,500,000 shares
Deferred Tax Assets, Net of Valuation Allowance $2,563,000 USD
Share-based Payment Arrangement, Expense $2,378,001 USD 213%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%